The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Utility of 18FDG-PET/CT for risk prediction in patients with R/R myeloma undergoing CAR-T therapy
Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, briefly discusses a study exploring the value of using 18FDG-PET/CT when treating patients with relapsed/refractory (R/R) multiple myeloma with CAR-T cells. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
